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Angesichts ihrer immunmodulatorischen, anti-fibrotischen und endothel-protektiven 
Eigenschaften, stellen mesenchymale stromale Zellen (MSZ) einen 
vielversprechenden Zelltyp für zell-therapeutische Interventionen dar. Das EU 
Komitee für zukunftsweisende Therapien unterstrich die Notwendigkeit von 
Strategien zur Selektion und Aufreinigung von MSZ, woraufhin das sulfatierte 
Proteoglykan CD362, welches auf der Zelloberfläche der MSZ zu finden ist, als neuer 
Kandidat identifiziert wurde. 
Ziel der vorliegenden Studie war es, den Einfluss von intravenös (i.v.) applizierten 
Wildtyp (WT), CD362-- und CD362+-selektieren MSZ auf die linksventrikuläre (LV) 
Funktion in Typ-2 diabetischen Mäusen zu vergleichen und die zugrunde liegenden 
Mechanismen zu untersuchen. Hierfür wurden 106 WT-MSZ, CD362-- bzw. 
CD362+-Zellen oder PBS i.v. in 20 Wochen alte diabetische 
BKS.Cg-m+/+Leprdb/BomTac db/db-Mäuse injiziert. Nicht diabetische 
db+/db-Mäuse, welchen PBS appliziert wurde, dienten als Kontrolle. Vier Wochen 
nach Applikation erfolgte die hämodynamische Charakterisierung und anschließende 
Euthanasie der Tiere. Für durchflusszytometrische Analysen wurde die Milz 
entnommen, sowie der LV für Immunhistologie, Molekularbiologie und bildgebende 
Massenspektrometrie. 
Die i.v. Injektion von WT-MSZ und CD362--Zellen, aber nicht von CD362+-Zellen, 
verbesserte die LV Funktion in den db/db-Mäuse, was sich in einer Verbesserung der 
Kontraktilitätsparameter dP/dtmax, dP/dtmin und/oder Tau zeigte (p <0.05). Bezüglich 
der Immunmodulation, erhöhte nur die Gabe der CD362+-Zellen den prozentualen 
Anteil an regulatorischen T Zellen (Tregs) in der Milz um das 1.3-fache (p<0.001), 
wohingegen WT-MSZ, CD362-- und CD362+-Zellen den Anteil an apoptotischen 
Tregs in der Milz verringerten (p<0.001 jeder Zelltyp gegenüber db/db-Mäuse). 
Verglichen mit den PBS-behandelten db/db-Mäusen war zusätzlich die Zahl an 
kardialen CD3+-Zellen um das 1.5-fache (p<0.05), 1.8-fache (p<0.01) und 1.7-fache 
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(p<0.01) nach Injektion von WT-MSZ, CD362-- bzw. CD362+-Zellen reduziert. 
Interessanterweise führte die Applikation von WT-MSZ, CD362-- bzw. 
CD362+-Zellen auch zu einer 1.6-fach (p<0.05), 1.8-fach (p<0.01) bzw. 1.6-fach 
(p<0.05) verringerten Zahl an kardialen CD68+-Zellen. Die hypothesenfreie 
Proteomanalyse mittels bildgebender Massenspektrometrie zeigte darüber hinaus eine 
verringerte Expression der Titin-Isoform N2B in den db/db-Mäusen gegenüber den 
db+/db-Mäusen, welche durch i.v. Anwendung aller untersuchten Zellen verbessert 
werden konnte. 
In Übereinstimmung mit der LV Funktion war die totale Titin-Phosphylierung in den 
db/db-Mäusen, im Vergleich zu den db+/db-Mäusen, um das 1.8-fache (p<0.01) 
herunterreguliert, welche nur durch die Applikation von WT-MSZ (1.6-fach; p<0.05) 
und CD362--Zellen (1.5-fach; p<0.05) induziert wurde. Parallel dazu, fiel die 
Proteinkinase G-Aktivität um das 1.5-fache (p<0.05) in den db/db-Mäusen gegenüber 
den nicht-diabetische db+/db-Mäusen und war in WT-MSZ und CD362- 
db/db-Mäusen wieder normalisiert. 
Abschließend kann gesagt werden, dass WT-MSZ und CD362--Zellen, aber nicht die 





Mesenchymal stromal cells (MSCs) are an attractive cell-type for cell therapy, given 
their immunomodulatory, anti-fibrotic, and endothelial-protective features. The EU 
Committee for Advanced Therapies highlighted the need for strategies of selecting 
and purifying MSCs, whereupon the cell-surface sulfated proteoglycan CD362 has 
been identified as a new candidate.  
The aim of the present study was to compare the impact of intravenous (i.v.) 
application of wildtype (WT), CD362-- and CD362+-selected MSCs on left 
ventricular (LV) function in type 2 diabetic mice and to investigate the underlying 
mechanisms. For this purpose, 106 WT-MSC, CD362-, or CD362+ cells or PBS were 
i.v. injected into 20-week-old diabetic BKS. Cg-m+/+Leprdb/BomTac db/db mice. 
Non-diabetic db+/db mice injected with PBS served as controls. Mice were 
hemodynamically characterized and sacrificed four weeks after cell or PBS 
application. Spleens were collected for flow cytometry and LVs for 
immunohistochemistry, molecular biology, and imaging mass spectrometry. 
I.v. injection of WT-MSC and CD362- cells, but not of CD362+ cells improved LV 
function in db/db mice as indicated by an improvement of the contractility parameters 
dP/dtmax, dP/dtmin and/or Tau (p<0.05). With respect to immune modulation, only 
CD362+ cells raised the percentage of splenic regulatory T cells (Tregs) by 1.3-fold 
(p<0.001), whereas WT-MSC, CD362-, and CD362+ cells all decreased the 
percentage of splenic apoptotic Tregs in db/db mice (p<0.001 each versus db/db mice). 
Additionally, the number of cardiac CD3+ cells was 1.5-fold (p<0.05), 1.8-fold 
(p<0.01), and 1.7-fold (p<0.01) reduced in db/db mice injected with WT-MSC, 
CD362-, and CD362+, respectively, compared to db/db mice. Interestingly, 
application of WT-MSC, CD362-, and CD362+ cells led to a 1.6-fold (p<0.05), 
1.8-fold (p<0.01), and 1.6-fold (p<0.05) decreased number of cardiac CD68+ cells. A 
hypothesis-free proteome analysis via imaging mass spectrometry further indicated a 
ABSTRACT（English） 
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lower expression of the titin isoform N2B in db/db versus db+/db mice, which could 
be overcome after i.v. application of all investigated cells. In agreement with the LV 
function, total titin phosphorylation was 1.8-fold (p<0.01) downregulated in db/db 
versus db+/db mice, which was only induced after application of WT-MSC (1.6-fold; 
p<0.05) and CD362- (1.5-fold; p<0.05). In parallel, protein kinase G activity dropped 
by 1.5-fold (p<0.05) in db/db versus non-diabetic db+/db mice and was normalized to 
control levels in WT-MSC db/db and CD362- db/db mice. 
In conclusion, WT-MSC and CD362- cells, but not CD362+ cells improve LV 
function in diabetic db/db mice via titin regulation. 
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ABC    avidin-biotin complex 
AGE   advanced glycated endproducts 
ANOVA  analysis of variance 
AP    alkaline phosphatase 
ASC   apoptosis-associated speck-like protein-containing protein 
α-SMA   alpha-smooth muscle actin 
ATMP    Advanced Therapy Medicinal Products 
BM    bone marrow 
BW    body weight 
Ca2+   calcium  
CD    cluster of differentiation  
cDNA    complementary DNA 
CI     cardiac index  
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dP/dtmax   maximum left ventricular pressure rise rate  
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EF    ejection fraction	
ELISA    enzyme-linked immunosorbant assay 
EU    European Union 
FOXP3   transcription factor forkhead box protein P3 
HbA1c   glycated hemoglobin A1c 
HF     heart failure 
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PBS    phosphate-buffered saline 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1.1.1. Definition - Diabetes mellitus 
Diabetes mellitus (DM) is a significant global health problem currently affecting over 
300 million people currently worldwide and an estimated about 450 million people by 
2030 [1]. DM is a multifactorial and metabolic disease, characterized by impaired 
metabolism of carbohydrate, fat, and proteins, as a result of the deficiency of insulin 
secretion, insulin action, or both. There are two major forms of DM. Type 1 is defined 
as insulin-dependent DM and type 2 is defined as non-insulin-dependent DM. Insulin 
is a hormone produced by the pancreas, which is primarily responsible for controlling 
blood glucose levels. Autoimmune destruction of ß cells, which produce insulin in the 
pancreas leads to type 1 DM, whereas insulin resistance with or without insulin 
deficiency leads to type 2 DM. Hyperglycemia is the key mark of DM. It increases the 
total number of free fatty acids, which leads to abnormalities in calcium homeostasis 
and lipid metabolism, and also promotes the production of reactive oxygen species, 
which promotes among others apoptosis in cardiomyocytes. 
DM can lead to serious diseases affecting the heart and blood vessels, nerves, eyes, 
kidneys, and limbs. In addition, people with diabetes also have a high risk of recurrent 
infections. Cardiovascular disease, particularly coronary artery disease, represents a 
leading cause of morbidity and mortality in patients with DM [1]. Because of these 
complications, especially coronary artery disease, DM is one of the top ten causes of 
death [2].  
 
 
1.1.2. Diabetic cardiomyopathy 
Diabetic cardiomyopathy is one of the most common causes of heart failure, 
contributing to the main mortality and morbidity rate of cardiomyopathy [3]. It was 
first discovered in 1972 by Rubler et al. [4] as a new type of specific cardiomyopathy, 
1. Introduction 
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described in an autopsy report from four diabetic patients who had congestive heart 
failure and normal coronary arteries. Then, in 1974, the definition of diabetic 
cardiomyopathy was given by Hamby et al. [5]. Diabetic cardiomyopathy can be 
described as a cardiac disorder with myocardial structural and functional changes, in 
the absence of coronary artery disease, chronic hypertension and significant valvular 
disease [6][7]. Epidemiological, clinical, and experimental studies during the past 
three decades subsequently confirmed the existence of diabetic cardiomyopathy. Still 
at present, diabetic cardiomyopathy is a poorly understood “entity” [8] and there is no 




Although several epidemiological studies demonstrate an increased risk of heart 
failure in diabetic patients [9][10], the prevalence and natural history of diabetic 
cardiomyopathy remains rarely defined. In the year 2014, Sanjay selected 2042 
residents randomly, aged 45 years or older over a 3 years period [11]. All patients 
underwent echocardiographic assessment of systolic and diastolic function. The 
diagnosis of diabetic cardiomyopathy was made in 23 people, corresponding to a 
community population prevalence rate of 1.1%. Among diabetic patients, 16.9% met 
the standard of diabetic cardiomyopathy and 54.4% had diastolic dysfunction. DM 
was associated with an average 1.9-fold increase in the risk of any left ventricular 
dysfunction, which can be separately described as a 1.7-fold increase in the risk of 
diastolic dysfunction, and a 2.2-fold increase in the risk of systolic dysfunction. 
Among patients with diabetic cardiomyopathy, the morbidity and mortality of patients 
with diabetic cardiomyopathy are high, approaching 31% over a period of 9 years. 
 
1.1.4. Pathogenesis of diabetic cardiomyopathy 
Diabetic cardiomyopathy is associated with impaired cardiac function due to 
cardiomyocyte hypertrophy [12], interstitial and perivascular fibrosis [13][14][15], 
intramyocardial microangiopathy [16], interstitial inflammation [17], abnormal 
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intracellular calcium (Ca2+)-handling [18], endothelial dysfunction [19], 
cardiomyocyte stiffness [20][21], and/or a defect in substrate metabolism [22]. The 
pathogenesis of diabetic cardiomyopathy is multifactorial. Hyperglycemia, 
hyperinsulinemia, and dyslipidemia, each trigger cellular signaling leading to specific 
alterations in cardiac structure [23][24] (Figure 1). These processes are not mutually 
exclusive and are likely to occur synergistically. The pathological relevance of each 
of the different metabolic perturbations that accompany diabetes, including 
hyperglycemia, hyperinsulinemia, and dyslipidemia, and the cellular consequences 
leading to altered myocardial structure and function still remains not fully understood 
[25]. 
The relevance of the duration and severity of hyperglycemia is reflected in the 
incidence of diabetic cardiomyopathy in patients with DM [24]. Several studies have 
demonstrated that hyperglycemia directly causes cardiac damage, contributing to the 
development of diabetic cardiomyopathy. Hyperglycemia induces oxidative stress by 
triggering the generation of reactive oxygen species (ROS) via increasing glucose 
oxidation, leading to the generation of advanced glycated end-products (AGE) and 
mitochondrial generation of superoxide on the one hand and by decreasing the 
production of antioxidant enzymes on the other hand [26]. This has a negative 
influence on Ca2+ homeostasis and leads to the production of irreversible crosslinks 
between extracellular matrix (ECM) proteins [27] and impairs contractile function 
(Figure 1). 
Animal models with hyperinsulinemia without hyperglycemia have increased left 
ventricular mass and diastolic dysfunction, in the absence of systolic dysfunction. 
Hypertrophy is thought to be mediated via the insulin growth 
factor/phosphatidyl-inositol-3-kinase-Akt signaling axis [28] (Figure 1). 
Hyperlipidemia, including increased triglycerides and non-esterified fatty acids, plays 
not only a central role as a trigger in cellular insulin resistance but also in the 
development of myocardial contractile dysfunction. The increased uptake of free fatty 
acids in the diabetic heart may lead to cell apoptosis/death [29]. These unoxidized 
free fatty acids can cause lipotoxicity, via conversion of FFA to harmful ceramide, 
 15 
which can induce cellular apoptosis through the induction of NF-κB, caspase 3 
activity, and cytochrome c release [25][30] (Figure 1). 
 
 
Figure 1. Scheme representing how diabetes mellitus-associated triggers can induce 
cardiomyopathy. The relationship between the metabolic triggers (non-esterified fatty acids 




1.1.5. Diabetic mouse models 
In order to perform research on DM, several animal models have been developed in 
rodents (rats and mice) [31][32], dogs [33], horses [34], and other mammals. 
Both models of type 1 and type 2 DM are available in rodents. To create Type 1 DM, 
mice are injected 1 or 5 days with streptozotocin (STZ), depending on the different 
dose used. STZ induces DM via its cytotoxic effect on the ß cells of the pancreas 
through DNA damage [35]. As a result of its action, ß cells undergo destruction by 
necrosis.  
Obesity can be the result of natural mutations or genetic manipulation. Alternatively, 
obesity can occur by a high-fat feeding experiment. Monogenic models of obesity 
commonly used in type 2 diabetes research are the Lep ob/ob mouse, which is 
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deficient in leptin, and the Lepr db/db mouse and Zucker Diabetic Fatty (ZDF) rat, 
which are deficient in the leptin receptor. Polygenic models include the KK mouse 





Mesenchymal stromal cells (MSCs) are self-renewable multipotent stromal cells that 
have the potential to differentiate into various lineages, including bone, cartilage, and 
adipose tissue [39][40]. In 2006, the minimal criteria for multipotent MSCs were 
defined in a position statement of the International Society for Cellular Therapy [41]. 
These minimal criteria include 1) the ability to adhere to plastic in standard culture 
conditions; 2) the expression of cluster of differentiation (CD)73, CD90, and CD105 
and the lack of expression of the hematopoietic surface molecules CD14, CD34, 
CD45, CD11b, CD79 α, CD19 and HLA-DR [41] (Figure 2) and 3) the capacity to 




Figure 2. Specific surface antigen expression of mesenchymal stromal cells. MSCs are 




In the bone marrow (BM) where MSCs were originally identified by Friedenstein et 
al. [42] in 1987, MSCs represent a rare population of ~1 in 10,000 nucleated cells and 
1.2. Mesenchymal stromal cells 
1.2.2. Bone marrow-derived mesenchymal stromal cells 
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they are 10-fold less abundant than hematopoietic stem cells [43]. They can be easily 
grown and expanded in culture [44]. For several decades, separation methods have 
been improved, and BM-derived MSCs have been used in numerous studies [45][46]. 
Meanwhile MSCs have been retrieved in virtually all post-natal organs and tissues 
[27], including the heart [32], fetal thymus [47], fetal pancreas [48], fetal liver [49], 
placenta [50][51], endometrium [52], umbilical cord blood [53], scalp tissue, and 




Besides their ease of culture, MSCs are especially attractive for cell therapy, given 
their immunomodulatory properties [55][56], their capacity to home to damaged 
tissues [57][56], and their low immunogenic nature, allowing allogeneic use [58]. 
With respect to cardiac repair, MSCs have been demonstrated to be able to 
differentiate into cardiomyocytes, endothelial cells, and smooth muscle cells [59]. 
However, the cardioprotective effects of MSCs are mainly attributed to facilitating 
endogenous repair via the release of paracrine factors including vascular endothelial 
growth factor, hepatocyte growth factor, stromal-derived factor 1, stem cell factor, 
and others, via which they exert their immunomodulatory [60][61], anti-oxidative 
[61], anti-fibrotic [62][56], anti-apoptotic [61], and pro-angiogenic effects [63][64] 
(Figure 3). 
MSCs have also been demonstrated to have an anti-diabetic therapeutic potential in 
spontaneous autoimmune NOD- and STZ-induced diabetic mice [65][66]. Despite the 
ability of MSCs to differentiate into insulin-producing cells, the percentage of 
pancreatic islets derived from MSCs after in vivo administration is small. Therefore, 
the anti-diabetic effect of MSCs after in vivo administration is again mainly thought to 
be due to their ability to repair pancreatic ß cells, increase islet capillary density and 
reduce ß-cell apoptosis in a paracrine manner [67] (Figure 3). 
 
1.2.3. Mesenchymal stromal cells for (cardiac) cell therapy 
 18 
 
Figure 3. Therapeutic capacity of MSCs. 
 
Importantly, MSCs are “clever” cells since they adapt to the environment/danger 
signals they are exposed to. For example, MSCs have pro-angiogenic features. 
However, in the context of tumorigenesis, anti-angiogenic properties of MSCs have 
been identified [68]. Furthermore, MSCs suppress T cell proliferation [69] and 
differentiation [70], but in the absence of exogenous inflammatory cytokines or T cell 




After the discovery that BM-derived MSCs have the biological property of 
differentiating into mesenchymal lineages, BM-derived MSCs were thought to play a 
leading role in the normal turnover and maintenance of adult mesenchymal tissues 
[72]. As a result, MSCs became an attractive cell source for therapeutic applications 
in multiple fields of regenerative medicine. The most obvious application was to 
apply MSCs in mesenchymal tissue, e.g. for bone and cartilage regeneration. Actually, 
the first studies tried to use MSCs for repairing bone defects and for the treatment of 
1.2.4. Clinical applications
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various bone diseases [73], including osteogenesis imperfecta, which defines a 
heterogeneous group of genetic disorders characterized by bone fragility and bone 
deformities such as osteoporosis. Clinical trials with MSCs have been started to treat 
children with osteogenesis imperfecta, which achieved good results [74][75]. 
There are currently several clinical trials evaluating the safety and efficacy of MSCs 
for treating diverse diseases, including idiopathic pulmonary fibrosis, chronic 
obstructive pulmonary disease [76], liver disease [77], heart disease [78][79] and DM 
[80]. With respect to heart disease, intracoronary MSCs application has been 
demonstrated to be save and to improve left ventricular (LV) ejection fraction (EF) 
and/or reduce scar tissue and improve myocardial perfusion in patients with 
ST-elevation after acute myocardial infarction [78][81][82]. Transendocardial MSCs 
injection has also been shown to improve LV function and/or ventricular remodeling 
and quality of life in patients with chronic ischemic cardiomyopathy [83][84]. Hare et 
al. [85] further showed for the first time that also intravenous (i.v.) application is safe 
and improves EF in myocardial infarction patients. Recently, Butler et al. [86] 
confirmed the safety and efficacy of the i.v. administration route in patients with 
non-ischemic cardiomyopathy. I.v. MSCs injection caused immunomodulatory effects 
and was associated with improvements in health status and functional capacity. 
With respect to diabetes, nine clinical safety trials are currently ongoing and one has 
been finalized [80]. 
 
 
1.2.5. CD362 and CD362-selection of bone marrow-derived mesenchymal stromal 
cells 
CD362, also called syndecan-2, is a heparan sulfate proteoglycan (HSPG). HSPGs are 
found at the cell surface and in the ECM and interact with a plethora of ligands, 
leading to a series of activations. HSPGs influence among others cell migration in the 
ECM, like cell-ECM attachment, cell movement, and cell-interaction. Furthermore, 
they bind cytokines, chemokines, and growth factors to protect them from proteolysis. 
HSPGs also affect angiogenesis [87]. Syndecan-1 is involved in inflammation and 
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fibrosis after myocardial injury and remodeling [88][89], and it plays a role in heart 
failure [90]. While syndecan-4 expression has been found in the infarcted region after 
myocardial infarction [91], the role of syndecan-2 (CD362) in heart disease has not 
been demonstrated before. 
CD362 is expressed in cells of mesenchymal origin and in the main syndecan expressed 
during embryonic development [92]. CD362 expression can be detected in adult human 
BM and umbilical cord, and in mouse-digested/flushed marrow, adipose muscle tissue 
and lymphoid stromal cell populations [93][94].  
The firm Orbsen Therapeutics Ltd (Galway, Ireland) defined CD362 as a marker to 
select MSCs from the mixture of BM cells, enabling the collection of a clearly defined 
population of MSCs from the BM of human donors. With the aim to use MSCs as a 
clinical product, this ability is expected to become a prerequisite for cell therapy 
products. In fact, the current standards of the European Union for defining a 
MSC-based Advanced Therapy Medicinal Products (ATMP) are very basic and focus 
on MSCs sterility and toxicology. However, both the European Union and the British 
Standard Institute highlight the BM-plating method of purifying MSCs as inadequate 
for defining or purifying MSCs for clinical use, as only 1:100,000 BM-derived MNCs 
plated are MSCs. The use of an anti-CD362 antibody, which allows MSCs to be 
selected from the BM beyond the MSCs/MNCs purity ratio of 1:13, a ratio obtained 
with a mixture of other antibodies directed against MSCs (communications form 
Orbsen Therapeutics Ltd). This superior ability of selecting a clearly defined 
population of MSCs formed the base of the “Repair of Diabetic Damage by Stromal 
Cell Administration” (REDDSTAR) Consortium of the European Commission 7th 
Framework, by which the efficacy of novel CD362+ versus CD362- and unselected 
MSCs in alleviating diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, 
diabetic cardiomyopathy and wound ulceration was evaluated.  
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Despite advances in anti-diabetic therapies and patient self-management, DM 
represents a growing medical and economic problem. Glycemic control remains 
sub-optimal in many patients who develop significant secondary complications. One 
of the common complications of DM is diabetic cardiomyopathy, a specific cardiac 
disorder associated with cardiac dysfunction and cardiac structural alterations.  
BM-derived MSCs are a mixed population of plastic-adherent cells with 
cardioprotective properties known to improve experimental diabetic cardiomyopathy. 
However, with the aim to have a clinical therapeutic cell product, a clearly defined 
population of MSCs is required, which has been shown to be possible via CD362 
selection. Within the REDDSTAR consortium, this study was focused on 
investigating the efficacy of CD362+- versus CD362-- and unselected MSCs in 
alleviating diabetic cardiomyopathy in an experimental model of type 2 DM, the 







Table 1. Consumption materials 
Article Description Company 
96-well Multiply®-PCR 
plate 
 Sarstedt, Nümbrecht, Germany 
Cell Strainer  70 µm BD Biosciences, New Jersey, USA 
Coverslips 21 x 26 mm R. Langenbrinck, Emmendingen, 
Germany 
Cryotubes 1.5 ml Carl Roth, Karlsruhe, Germany 
Falcon tubes 15 ml, 50 ml Corning, New York , USA 
Folded filter  MN615 1/4·¢240 
mm 
Macherey-Nagel, Duren, Germany 
Gloves  Sempercare, Northamptoshire, 
Germany 
Masks  Charite, Berlin, Germany 
MicroAmp®Optial 
384-well plate 
Reaction plate with 
Barcode 




A35 type Pfm medical ag, Köln, Germany 
PCR-tubes 0.2 ml, conical lid Biozym, Hess. Oldendorf, Germany 
Pellet pestle and tubes Dstry-SR-15 and 
1.5 ml tubes 
Biozym, Hess. Oldendorf, Germany 
Pipette tips 10 µl, 100 µl, 1000 
µl 
Biozym, Hess. Oldendorf, Germany  
Pipettes  Corning, New York , USA 
3. Materials and methods 
3.1. Materials 
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Plastic cannulas 18G und 20G B.Braun, Melsungen, Germany 
Plunger 2.5 ml syringe TERUMO, Tokyo, Japan 
Reaction Tubes Safe-Lock or 
RNAse free 
Sarstedt, Nümbrecht, Germany 
Scalpels Feather®  Pfm medical ag, Köln, Germany 
Slides Super Frost Plus R.Langenbrinck, Emmendingen, 
Germany 
 
Table 2. Laboratory equipments 
Equipment Description/Type Company 
Conductance catheter 1.2 French Scisense Inc., Ontario, Canada 
Cryostat  Microm, Minnesota, USA 
Freezer -20 °C Economic super Bosch AG, Stuttgart, Germany 
Freezer -80 °C Nuaire Ultralow 
Freezer 
Zapf Instrumente, Sarstedt, 
Germany 
Homogenizer Pellet Pestle Motor Sigma, Taufkirchen, Germany 
Horizontal shaker SM-25 Edmund Bühler, Tübingen, 
Germany 
Ice maker  AF-10 Scotsman, Vernon Hills, USA 
Incubator Function Line Heraeus, Osterode, Germany 
Microscope DMRBE Leica, Bensheim, Germany 
MACSQuant Tyto  Miltenyi Biotec, Bergisch 
Gladbach, Germany 
pH meter Knick Digital 646 Beyer, Düsseldorf, Germany 
Pipettes  Eppendorf, Wesseling-Berzdorf, 
Germany 
P-V Amplifier System MPVS 300/400 Millar Instruments, Houston, 
USA 
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Spectrophotometer NanoDrop Thermo Scientific PEQLAB, 
Erlangen, Germany 
Photometer SPECTRA max 
340PC384 
Molecular Devices, Biberach an 
der Riß, Germany 
Tabletop centrifuge Centrifuge 5415 C Eppendorf, Wesseling-Berzdorf, 
Germany 
Thermocycler Mastercycler gradient Eppendorf, Wesseling-Berzdorf, 
Germany 
Thermomixer Comfort Eppendorf, Wesseling-Berzdorf, 
Germany 
Ventilator Mini-Vent Harvard Apparatus, 
Massachusetts,USA 
Vortexer VF2 IKA-Labortechnik, Staufen, 
Germany 
 
Table 3. Buffer, reagents and kits 
Article Company 
1% ß-mercaptoethanol Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
3-amino-9-ethylcarbazole (AEC) Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
ABC Blocking Kit Vector Labs, Burlingame, USA 
ABC Kit Standard Vector Labs, Burlingame, USA 
Acetic acid VWR International GmbH, Darmstadt, 
Germany 
Acetone  VWR International GmbH, Darmstadt, 
Germany 
Avidin-Biotin-Blocking-Kit Vector Labs, Burlingame, USA 
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Bovine serum albumin (BSA) Carl Roth, Karlsruhe, Germany  
Calcium chloride VWR International GmbH, Darmstadt, 
Germany 
DeadEndTM Colorimetric TUNEL 
System 
Promega, Mannheim, Germany 
Dianova (secondary antibody) Dianova, Hamburg, Germany 
Di-Sodium hydrogen phosphate 
dihydrate 
VWR International GmbH, Darmstadt, 
Germany 
Distilled water Alleman Pharma GmbH, Rimbach, Germany 
DNAse I Qiagen, Hilden; Germany 
EDTA VWR International GmbH, Darmstadt, 
Germany 
EnVision K4003 Dako, Hamburg, Germany 
Ethanol  Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Fetal Bovine Serum (FBS) Biochrom, Berlin, Germany 
Fixation/Permeabilization kit BD Biosciences, New Jersey, USA 
Formalin Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
GLYCO-Tek Affinity Column Kit Helena Laboratories, Texas, USA 
Hemalum VWR International GmbH, Darmstadt, 
Germany 
High Capacity Archive Kit Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
High Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, Darmstadt, Germany 
Hydrogen peroxide solution Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
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Isopropanol Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Kaiser's glycerol gelatin Carl Roth, Karlsruhe, Germany 
Magnesium chloride VWR International GmbH, Darmstadt, 
Germany 
N, N-dimethylformamide Carl Roth, Karlsruhe, Germany 
Potassium chloride VWR International GmbH, Darmstadt, 
Germany 
Potassium dihydrogen phosphate VWR International GmbH, Darmstadt, 
Germany 
RNase-free water Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
RNeasy Mini Kit Qiagen, Hilden; Germany 
Sodium acetate VWR International GmbH, Darmstadt, 
Germany 
Sodium chloride VWR International GmbH, Darmstadt, 
Germany 
Sodium hydrogen phosphate VWR International GmbH, Darmstadt, 
Germany 
Tissue Tek Sakura, Zoeterwoude, Netherlands 
Tris-Base Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Tris-HCl VWR International GmbH, Darmstadt, 
Germany 






Table 4. Real-time-PCR reagents 
Reagents Company, ID 
Optical 384-well Reaction Plate Applied Biosystems, Darmstadt, Germany 
Optical Adhesive film Applied Biosystems, Darmstadt, Germany 
TaqMan®Gene Expression Master Mix 
(2×) 
Thermo Fisher Scientific, Waltham, 
Massachusetts, USA 
Universal PCR Master Mix Applied Biosystems, Darmstadt, Germany 
 
Table 5. Primers for Real-time-PCR 
Murine primers Ordering number Company, ID 
ASC Mm00445747_g1 Applied Biosystems, Darmstadt, Germany 
α-SMA Mm00725412_s1 Applied Biosystems, Darmstadt, Germany 
Caspase1 Mm00438023_m1 Applied Biosystems, Darmstadt, Germany 
CDKN1b Mm00438167_g1 Applied Biosystems, Darmstadt, Germany 
Col1a1 Mm01302043_g1 Applied Biosystems, Darmstadt, Germany 
Col3a1 Mm00802331_m1 Applied Biosystems, Darmstadt, Germany 
GAPDH Mm99999915_g1 Applied Biosystems, Darmstadt, Germany 
IL-10 Mm00439616_m1 Applied Biosystems, Darmstadt, Germany 
IL-1ß Mm00434228_m1 Applied Biosystems, Darmstadt, Germany 
Lox1 Mm00495386_m1 Applied Biosystems, Darmstadt, Germany 
Loxl2 Mm00804740_m1 Applied Biosystems, Darmstadt, Germany 
Nlrp3 Mm00840904_m1 Applied Biosystems, Darmstadt, Germany 
TGF-ß Mm00441724_m1 Applied Biosystems, Darmstadt, Germany 







Table 6. Antibodies for the immunohistochemical studies of cardiac tissue 
AB Company 
Anti-α-SMA Abcam, Cambridge, UK 
Anti-CD3 Santa-Cruz Biotechn, Heidelberg, Germany 
Anti-CD4 BD Bioscience, Heidelberg, Germany 
Anti-CD68 Abcam, Cambridge, Germany 
Anti-CD8a BioLegend, Koblenz, Germany 
Anti-Collagen I (secondary antibody) Merck Millipore, Darmstadt, Germany 
Anti-Collagen III (secondary antibody) Merck Millipore, Darmstadt, Germany 
 
 
Table 7. Antibodies for flow cytometry 
Antigen AB Company Cat.Nr. Volume of AB 




560506 5 µl 
CD4 Anti-CD4 FITC Miltenyi 
Biotec 





130-102-431 2.5 µl 
CD25 Anti-CD25 PE Miltenyi 
Biotec 





130-102-448 5 µl 











3.2.1. Study design 
In this study, 8-week-old heterogeneous (db+/db) and homogeneous (db/db) 
BKS.Cg-m+/+Leprdb/BomTac mice from Taconic (Skensved, Denmark) were used 
and housed under standard housing conditions (12 hour (h) light/dark cycle, 50-70% 
humidity, 19-21 °C). Leptin receptor (Lepr) knockout (KO) mice, commonly known 
as db/db mice, are a suitable model for studying the pathogenesis of type 2 
non-insulin-dependent DM. Only homogeneous mice are diabetic, whereas 
heterogeneous mice are non-diabetic. Once a week and before cell application, blood 
glucose (BG) was measured after 4h fasting. For cell treatment, db/db mice were 
randomly divided into 4 groups (Table 8). 
 
Table 8. Groups of mice in the study. 
Group  Number 
db+/db 9 
db/db 6 
db/db -WT-MSC 8 
db/db CD362- MSC 9 
db/db CD362+ MSC 9 
 
WT-MSC (WT), CD362-, and CD362+ cells from the same donor were provided by 
Orbsen Therapeutics Ltd. One million cells of each celltype were i.v. injected in 200 µl 
PBS in 20-week-old db/db mice. The control animals received the corresponding 
volume of PBS. After 4 weeks, mice were anesthetized and cardiac function was 
measured by conductance catheter. Subsequently, blood was taken and the left 
ventricle (LV) was immediately snap frozen in liquid nitrogen for molecular and 
immunohistochemistry examinations. Additionally, spleens were collected for flow 
cytometry. The experiments followed the European guidelines for the Care and Use of 
3.2. Methods 
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Laboratory Animals and approved by the local authority (Landesamt für Gesundheit 
und Soziales, G0254/13, Berlin, Germany). 
 
 
3.2.2. Characterization of cardiac function by conductance catheter 
3.2.2.1. Theoretical background of the conductance catheter technique 
Conductance is the reciprocal of electrical resistance and depends on the volume of 
the LV. The conductance catheter, which comprises a pressure (P) sensor and four 
electrodes, generating a permanent electric field to measure the potential difference 
between the electrodes. During the cardiac cycle, the physiological changes of LV 
volume alter the resistance and thereby the conductance of the blood. The electric 
field generated by the conductance catheter represents the total conductance from 
blood and surrounding tissues, especially from the LV. Thus, the calculated volume is 
overestimated and known as parallel conductance or parallel resistance. It has to be 
converted to correct volumes by subtracting the volume caused by the parallel 
conductance [95]. In this study, volume was corrected by the injection of 5-10 µl of a 
10% saline solution into the jugular vein. 
 
 
3.2.2.2. Parameters for cardiac function 





Formula or description Unit 
CO Cardiac output CO = HR × SV µl /min 
CI Cardiac index CI = CO / BW µl /min /g 
EF Ejection fraction EF = ((LVEDV − LVESV)/ 
LVEDV) × 100 
％ 
LVPmax Maximum LVP Maximum pressure generated by 
the left ventricle during systole. 
mmHg 
dP/dtmax Maximum LVP Contractility of the LV, which mmHg/s 
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rise rate describes the maximum speed of 
the P rise in the LV. 
dP/dtmin Minimum LVP 
drop rate 
The minimum rate of P change 
during the isovolemic LV 
relaxation. 
mmHg/s 
Tau Time of the LVP 
decrease 
Represents the exponential 






Mice were intraperitoneally (i.p.) injected with a mixture of buprenorphine (0.05 
mg/kg) + urethane (0.8-1.2 g/kg), 10-30 minutes (min) before starting the 
measurement. The depth of the anesthesia was checked by the response to tail or paws 




3.2.2.4. Intubation and ventilation 
Mice were fixed in supine position on a surgical platform and their necks were put in 
hyperextension position. Using surgical tape, the front paws, the tail, as well as the 
snout was fixed. The tape across the tip of the snout pulls the head slightly back to 
create traction on the trachea. Following a midline neck incision, the skin was pulled 
away from the underlying muscles and cut off. Surrounding tissues and the 
paratracheal muscles were gently removed from the trachea by using forceps. 
Afterwards, a small hole was cut onto the surface and the tracheostomy cannula was 
inserted, which was immediately connected to the respirator (Figure 4). Stroke 





Figure 4. Intubation and ventilation of the mice for hemodynamic measurement. 
 
 
3.2.2.5. Surgical procedures 
The abdomen was opened with scissors in a transverse incision. To avoid excessive 
bleeding, the blood vessels were blocked with a cauter. Afterwards, an incision over 
the xiphoid process was made and the chest was opened. The edge of the diaphragm 
was cut to expose the apex of the heart. The pericardium was gently removed from 
the heart with forceps. A 25–30 gauge needle was used to punch circa 2-4 mm in the 
apex into the LV. After the needle was removed, the catheter tip was inserted into the 







Figure 5. Surgical procedures of hemodynamic surgery. 
 
 
3.2.2.6. Recording of pressure-volume loops by conductance catheter 	
In this study, the pressure-volume (PV) data of the LV were recorded in real time 
with the conductance catheter technique. With this method, it is possible to determine 
both volume-dependent and independent parameters describing the heart function. 
The catheter was connected to a PV-amplifier system and data were collected using 
the "IOX", 1.8.9 software (EMKA Technologies, Falls Church, USA). For analyzing, 
the program "Circlab 2004" (Paul Steendijk, GTX Medical Software, Belgium) was 
used. 
For the recording, the position of the catheter was adjusted to obtain 
rectangular-shaped PV loops. The small animal respirator was shut off for 5 seconds 
(sec) to acquire data without lung motion artifacts. After stabilization of the signal, 
baseline PV loops at steady-state conditions were recorded 3 times. After recording 
the steady-state, 10% sodium chloride was injected into the jugular vein for volume 
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calibration. Analogous to the steady-state, the small animal respirator was shut off. 
Finally, the inferior vena cava was occluded for 1-2 sec and data were recorded as 
described above (Figure 6). At the end of the experiment, the catheter was removed 
and mice were euthanized by cervical dislocation.  
 
 
Figure 6. Recording of pressure-volume loops by conductance catheter. 
 
 
3.2.3. Glycated hemoglobin kit 
The Helena GLYCO-Tek kit (Helena Laboratories, Texas, USA) was used for the 
quantitation of a certain glycated hemoglobin fraction (HbA1c) in whole blood 
samples. 50 µL of whole blood was placed in a tube and 400 µL GLYCO-Tek 
Hemolysate Reagent was added. To ensure complete hemolysis of the sample, the 
tube was vortexed. Afterwards, 100 µL of sample hemolysate was loaded onto the 
prepared GLYCO-Tek affinity columns, which were placed on the corresponding 
collection tubes. Next, the sample was allowed to set for 8 min, followed by washing 
each column with 0.5 ml GLYCO-Tek Developer A. Subsequently, additional 4 ml 
GLYCO-Tek Developer A was applied to the column with the large collection tube. 
The resulting eluate was adjusted to 15 ml with deionized water containing 
non-glycated hemoglobin (GHb). The column was then placed over the smaller 
collection tube and 3 ml GLYCO-Tek Developer B was added. The total eluent of the 
column contained GHb. Finally, both collection tubes were inverted 3 times and 
transferred to a cuvette. Immediately, absorbance of the GHb and non-GHb solution 
at 415 nm was measured. 
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The percentage of HbA1c was calculated from the percentage of GHb by using the 
provided algorithm according to the manufacture’s protocol. 
 
 
3.2.4. Molecular methods 
3.2.4.1. RNA extraction 
RNA isolation was performed by using the TRIzol™ (Invitrogen, Heidelberg, 
Germany) method to isolate total RNA from tissue samples. For this purpose, frozen 
LV tissues were placed into a FACS tube containing 1 ml TRIzol™ reagent, and 
homogenized for 30 sec The homogenized samples were transferred to a 1.5 ml tube 
and 200 µl Chloroform was added. Samples were shaken for 15 sec and then 
incubated at room temperature (RT) for 2 min. After incubation, tubes were 
centrifuged with an acceleration of 10,000 rpm for 15 min at 4 °C. After 
centrifugation, the colorless upper phase containing the RNA, was carefully 
transferred into a new 1.5 ml tube. To precipitate the RNA, 500µl of 100% 
isopropanol was added to the sample and incubated at RT for 15 min, followed by 
centrifugation at 10,000 rpm for 10 min at 4 °C. To wash RNA pellets, 500 µl Ethanol 
(70%) was added and the samples were vortexed. After one more centrifugation for 
10 min at 4 °C and with an acceleration of 7,500 rpm, the supernatant was removed 
and the remaining RNA pellets were dissolved in 100 µl RNase-free water. For 
purification, the NucleoSpin® RNA mini kit (Macherey-Nagel GmbH, Düren, 
Germany) was used according to the manufacturer's protocol. In detail, each sample 
was supplemented with 300 µl RA1 buffer and 300 µl ethanol (96%). Now, the 
lysates were loaded onto a NucleoSpin® RNA II column placed in a rack. After the 
next centrifugation at 12,000 rpm for 30 sec, columns were placed into a collection 
tube and 350 µl membrane desalting buffer was added. Additionally, a centrifugation 
at 12,000 rpm for 1 min was performed, followed by DNA digestion. For this purpose, 
10 µl reconstituted rDNase was mixed with 90 µl reaction buffer and incubated for 15 
min at RT. Subsequently, silica membranes were washed 3 times with 200 µl RA2, 
600 µl RA3, and 250 µl RA3, respectively. Between washings, samples were 
 36 
centrifuged for 30 sec at 12,000 rpm and the flow-through was discarded. Last 
centrifugation step was performed for 2 min and the column was placed into a 1.5 ml 
tube afterwards. To elute the RNA, 50 µl RNase-free water was used and centrifuged 
at 12,000 rpm for 1 min. 
The concentration of RNA was measured at the absorbance of 260 nm by using a 
NanoDrop 1000 (Thermo Scientific, Erlangen, Germany). 
 
 
3.2.4.2. Reverse Transcription 
The High Capacity cDNA Reverse Transcription Kit from Applied Biosystems 
(Darmstadt, Germany) was used to perform reverse transcription, the generation of 
complementary DNA (cDNA) from RNA, from the isolated RNA. For this purpose, 1 
µg RNA was filled up to a total volume of 11 µl with RNase-free water, and 2.8 µl 
random primers and dNTP´s were added. Random primers and template RNA were 
heated for 5 min at 70 °C in a thermocycler. Meanwhile, a master-mix was prepared 
by mixing the appropriate volumes of the following components: 2 µl buffer + 3.2 µl 
RNase-free water, and 1 µl reverse transcriptase. The heated tubes were directly put 
on ice and mixed with 6.2 µl of the mastermix. Reverse transcription was performed 
in a thermocycler according to the following program: 10 min at 25 °C, 2 h at 37 °C, 
followed by an additional 5 min at 85 °C and cooling to 4 °C. At the end of the 
reverse transcriptase, 30 µl RNase-free water was added to each sample to reach a 
final volume of 50 µl. 
 
 
3.2.4.3. Real-time	polymerase	chain reaction 
To evaluate the relative gene expression of different targets in the LV of the mice, a 
real-time polymerase chain reaction was performed using a mixture of 5 µl PCR 
master-mix, 0.5 µl gene reporter assay (both Life Technologies GmbH, Darmstadt, 
Germany), and 3.5 µl water.  
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The reporter assays include forward and reverse primers as well as the fluorescently 5’ 
6’FAM-labelled probe, with the 3’ non-fluorescent Quencher NFQ-MGB). The 
volume of cDNA used is mentioned above (Table 5). For the amplification of the 
sample, which is measured in duplicates, the 7900HT real-time system (Applied 
Biosystems, Darmstadt, Germany) with the subsequent program was used. First, 
addition at 50 °C for 2 min followed by an initial denaturation at 95 °C for 10 min. 
After the second denaturation at 95 °C for 15 sec, annealing and elongation at 60 °C 
for 1 min were performed. Depending on the target gene, the last two steps were 
repeated 40 or 45 times. 
 
3.2.4.4. Housekeeping genes 
We screened the Ct values of the housekeeping genes GAPDH and CDKN1b to 
determine which housekeeping gene could be used for normalization of the target 
gene data (Figure 7). 
 
Figure 7. Evaluation of the Ct values of GAPDH and CDKN1b among the different 
experimental groups for housekeeping gene selection. Ct values of A. GAPDH and B. 
CDKN1b in db+/db, db/db, and db/db mice receiving WT-MSC, CD362- or CD362+ cells. 
One-way ANOVA test. *p<0.05, with n=9 for db+/db, n=6 for db/db, n=8 for WT-MSC, n=9 
for db/db CD362-, and n=9 for db/db CD362+. 
 
There were no significant differences between the Ct values of GAPDH among the 
different groups, whereas the Ct values of CDKN1b were significantly different 
between db+/db and db/db, and db+/db and db/db CD362+. Consequently, we used 
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GAPDH as housekeeping gene. Data were further normalized against GAPDH, which 
served as an endogenous control using the 2-ΔCt formula. To examine the n-fold 
change, mRNA levels were normalized to the db+/db group set as 1. 
 
3.2.5. Immunohistochemistry 
3.2.5.1. Generation of frozen sections 
To obtain cryoslides from the LV, tissue samples were embedded in Tissue-Tek OCT 
(Sakura, Zoeterwoude, NL). Afterwards, they were cut into 5-µm-thick transverse 
sections using the cryostat (Microm, Minnesota, USA). Subsequently, the sections 
were immersed in ice-cold acetone for 10 min. After drying, the slides were 
immediately used for staining or stored at -20 ◦C. 
 
3.2.5.2. Immunohistological staining 
Immunohistochemistry (IHC) refers to the principle of specific antibody-antigen 
binding in a biological tissue [96]. In this study, two methods were used: the 
Avidin-biotin complex (ABC) method and the EnVision® method, depending on the 
biomarker investigated (Table 10). 
 
Table 10. Antibodies for immunohistochemistry: species, dilution, and method 
used. 
1. AB Species Dilution 2.AB Species Dilution Method 
α-SMA Rabbit 1:200 EnVision  Anti-Rabbit — EnVision 
CD3 Goat 1:75 ABC-Kit Anti-Goat 1:250 ABC 
CD4 Rat 1:50 Dianova Anti-Rat 1:250 ABC 
CD8a Rat 1:50 Dianova Anti-Rat 1:250 ABC 
CD68 Rabbit 1:600 Dianova Anti-Rabbit 1:250 ABC 
Col I Rabbit 1:350 EnVision Anti-Rabbit — EnVision 
Col III Rabbit 1:200 EnVision Anti-Rabbit — EnVision 




The EnVision® method was used to investigate cardiac collagen I, collagen III, and 
α-SMA expression. It is a two-step staining, combining the secondary antibodies with 
horseradish peroxidase (HRP) or alkaline phosphatase (AP) as detection system.  
Procedure of the EnVision® method: 
First, slides were washed once with 1x PBS for 5 min followed by adding 0.075% 
H2O2 for 7 min to block the endogenous peroxidase. Subsequently, slides were 
washed twice with 1xPBS, each time for 5 min on a shaker. Afterwards, 75-100 µl of 
the primary antibody (1.AB) was added to every section and slides were stored for 60 
min in a moist vessel. Slides were washed twice again followed by addition of 75-100 
µl of the secondary antibody (2.AB) and stored for 30 min in a moist vessel. As 
described above, additional washing was performed and slides were incubated for 12 
min in the dark with substrate solution. Before hemalum staining, slides were washed 
again once with 1x PBS, and after 30 sec of staining 4-5 times with cold tap water. 
 
 
3.2.5.4. Avidin-biotin complex method 
The avidin-biotin complex (ABC) method is characterized by the extraordinary 
affinity of avidin for biotin, which allows specific binding between biotin-containing 
molecules and avidin. This method was used in this study to determine the presence 
of inflammatory cells such as CD3, CD4, CD8a and CD68. 
Procedure of the ABC method: 
As already described for the EnVision® method, slides were first washed and 
endogenous peroxidase was blocked. In contrast to the EnVision® method, 1x TBS 
was used instead of 1x PBS for all washing steps, but also for 5 min on a shaker. 
Afterwards, 75-100 µl of a mixture containing 10% normal serum (depending on the 
species of the 2.AB), 1% BSA in 1x TBS, and 4 drops/ml Avidin was added to each 
section and stored for 30 min in a moist vessel. After adding 75-100µl antibody 
solution, which was supplemented with 1% BSA in 1x TBS, and 4 drops/ml Biotin, 
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the slides were kept for 60 min in the moist vessel. Subsequently, washing was 
performed twice and 75-100 µl of the 2.AB mixed with 1% BSA in 1x TBS was 
added for 60 min incubation. After washing twice with 1xTBS, and once with 1xTBS 
supplemented with 0.01% Tween, ABC-Solution was added (75-100 µl / section) and 
incubated for 30 min. Again, slides were washed 2 times followed by addition of the 
substrate solution for 12 min in the dark. Slides were washed twice and stained with 
hemalum. Finally, they were washed as described above. 
 
 
3.2.6. Flow cytometry 
To determine the immunomodulatory effects of MSCs application in diabetic db/db 
mice, flow cytometry was performed. For this purpose, the spleen of PBS- or 
cell-treated mice was collected and a single cell suspension was prepared. The 
collected spleens were positioned in a petri dish containing RMPI media. Afterwards, 
the spleens were mashed through a 70 µm cell strainer using the plunger of a 2.5 ml 
syringe. Subsequently, the cell strainer was flushed with 15 ml 1% FBS in 1xPBS. 
Afterwards, the solution was centrifuged for 5 min at 3500 rpm and RT. The 
supernatant was carefully aspirated and the remaining pellet was resuspended in 6 ml 
ACK lysis buffer. After 4 min incubation, lysis of the erythrocytes was stopped with 
40 ml RPMI. Now, the cell suspension was passed through a 40 µm cell strainer and 
centrifuged at RT and 3500 rpm for 5 min. Subsequently, the supernatant was 
aspirated, and the cell pellet was resuspended in 2 ml FBS supplemented with 10% 
DMSO and stored at -80 °C for further analysis. 
 
 
3.2.6.1. Investigation of splenic regulatory T cells  
To analyze splenic regulatory T cells (Tregs), the mouse Tregs detection kit (Miltenyi 
Biotec) was used. Isolated splenocytes were defrozen. Afterwards, 1x106 cells were 
resuspended in 85 µl binding buffer, which had previously been diluted 1/10 with 
water. The corresponding volume (Table 7) of CD4, CD25 and Annexin V V450 (BD 
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Bioscience, Heidelberg, Germany) AB was added to the solution and incubated for 20 
min at 4℃ in the dark. Then, splenocytes were washed and centrifuged (always at 
3000 rpm for 5 min at 4℃ ). After aspiration of the supernatant, cells were 
resuspended in 1 ml of cold, freshly prepared fixation/permeabilization solution and 
incubated 30 min at 4℃  in the dark. Following washing, and additional 
centrifugation, the cell pellet was resuspended in 80 µl of cold 1x permeabilization 
buffer for 15 min incubation. After that, cells were incubated for 30 min at 4 °C in the 
dark with a FoxP3 AB. For washing, cells were resuspended by adding 1 ml of cold 
1x permeabilization buffer followed by additional centrifugation. To perform flow 
cytometry analysis, the cell pellet was resuspended in a suitable volume of PBS and 
measured on a MACSQuant Analyzer (Miltenyi Biotec). Further analysis was 
performed using the FlowJo software version 8.8.6. (Tree Star Inc., USA). 
 
 
3.2.6.2. Investigation of splenic cytokine production 
As described above, splenocytes were defrozen. Afterwards cells were plated at a 
density of 1x106 cells/well in 96-well U-bottom plates (n=5 wells per condition) in 
Iscove medium (Sigma) containing 10% FBS and 1% P/S. To determine splenic 
cytokine production, cells were further stimulated with PMA/Ionomycin (BD 
Biosciences) at a final concentration of 50 ng/ml and 500 ng/ml in 6 ml Iscove 
medium. Finally, 4 µl of BD GolgiStop™ (BD Biosciences) was added for every 6 ml 
of the stimulation media with overnight incubation in the dark. On the next day, cells 
were collected, centrifuged and washed with PBS containing 1% FBS. First, cell 
surface staining of CD68 was performed followed by intracellular staining. For this 
purpose, cells where incubated with 300 µl fixation/permeabilization solution 
(Invitrogen) for 20min at 4 °C. To wash the cells, 1ml BD Perm/Wash™ buffer 
(Invitrogen) was added and samples were centrifuged. To stain for intracellular 
cytokines, 42.5 µl BD Perm/Wash™ buffer supplemented with TGF-β AB was added 
for 30 min at 4 °C in the dark. After additional washing, the cell pellet was 




3.2.6.3. Investigation of splenocyte activation and proliferation 
Splenocytes were defrozen and labeled with CFSE (CellTrace™ CFSE Cell 
Proliferation Kit; lifetechnologies). Subsequently, 1x106 cells were resuspended with 
10 µM CFSE in 1 ml PBS containing 0.1% BSA and incubated for 15 min at 37℃. 
Then, splenocytes were washed and centrifuged at 3000 rpm for 5 min. After 
discarding the supernatant, labeled cells were plated at a density of 1x106 cells/well in 
96 U-bottom well plates (n=5 wells per condition) in Iscove medium (Sigma) 
containing 10% FBS and 1% P/S. Subsequently, cells were stimulated with 
PMA/Ionomycin at a final concentration of 50 ng/ml and 500 ng/ml in 6 ml Iscove 
medium, with overnight incubation in the dark. On the following day, cell surface 
staining of CD4 and CD8 was performed. After additional washing, the cell pellet was 
resuspended in 200 µl PBS for flow cytometry analysis. 
 
 
3.2.7. Heart section analysis by MALDI-Imaging mass spectrometry 
 MALDI-imaging mass spectrometry (IMS) was performed by Dr. Oliver Klein 
(corefacility proteomics, BCRT, Charité - Universitätsmedizin Berlin) according to an 
already established protocol [97]. 
In brief, paraformaldehyde (PFA)-fixed tissue samples of the LV were dehydrated by 
washing and embedded in paraffin. Afterwards, sections of 7 µm were prepared and 
transferred onto Indium-Tin-Oxide slides (Bruker Daltonik, Bremen, Germany). 
Samples were dewaxed and incubated with trypsin solution. According to the 
manufacturer’s protocol, matrix solution was applied followed by MALDI-IMS. Data 
acquisition was performed on an Autoflex III MALDI-TOF/TOF with flexControl 3.0 
and flexImaging 3.0 software (Bruker Daltonik) in a raster width of 80 µm. To 
determine regions of interest, tissue sections were stained after MALDI-IMS with 
hematoxylin and eosin (H/E). To identify proteins, the “bottom-up”-nano liquid 
chromatography (nLC) - MS/MS (nUPLC-MS/MS) approach was performed on an 
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adjacent tissue section. Comparison of MALDI-IMS and nUPLC−MS/MS data via a 
Mus musculus protein database downloaded from the UniProt database UniProt 
enables the identification of several peptides. 
To assess statistical differences, data from each group were compared pairwise by 
using receiver operating characteristic (ROC, AUC < 0.4) analysis. P-values were 




3.2.8. Investigation of cardiac titin 
The analysis of the phosphorylation state of cardiac titin and of protein kinase G 
activity was performed in cooperation with Dr. Nazha Hamdani (Department of 




3.2.8.1. All-titin phosphorylation by Pro-Q Diamond stain 
Frozen tissues from LV mouse hearts were solubilized in 50 mM Tris sodium dodecyl 
sulfate (SDS) buffer (pH 6.8) supplemented with 8 µg/ml leupeptin (Peptin Institute, 
Japan) and phosphatase inhibitor cocktail (PIC [P2880], 10µl/ml; Sigma Aldrich). 
Afterwards, solubilized samples were heated, centrifuged, and separated on 
agarose-strengthened 1.8% sodium dodecyl sulfate-polyacrylamide gels. Following 
electrophoresis, gels were stained with Pro-Q Diamond phosphoprotein stain for 1h. 
According to the manufacturer’s guidelines (Thermo Fisher Scientific), fixation, 
washing and de-staining were performed. Finally, gels were stained overnight with 
SYPRO Ruby (Thermo Fisher Scientific) to assess total protein content. Signals were 
visualized using the LAS-4000 Image Reader (460 nm/605 nm Ex/Em; 2 s 





3.2.8.2. Myocardial protein kinase G activity 
LV tissue samples were homogenized to assess myocardial protein kinase G activity. 
For this purpose, tissue sections were treated with 25 mmol/l Tris (pH 7.4), 1 mmol/l 
EDTA, 2 mmol/l EGTA, 5 mmol/l dithiothreitol (DTT), 0.05% Triton X-100 and 
protease inhibitor cocktail (Sigma-Aldrich). Following centrifugation for 5 min, 
supernatants were incubated at 30 °C for 10min with a reaction mixture containing 40 
mmol/l Tris-HCl (pH·7.4), 20 mmol/l magnesium acetate, 0.2 mmol/l [32P] ATP 
(500-1000·c.p.m.·pmol–1; GE Healthcare LifeScience, Little Chalfont, UK), 
113·mg/ml heptapeptide (RKRSRAE), 3 mmol/l cGMP (Promega, Madison, 
Wisconsin, USA) and a highly specific inhibitor of cAMP-dependent protein kinase 
(5-24, Merck Millipore). Reaction was terminated by spotting 70 µl of the mix onto 
Whatman P-81 filters, which were then soaked with 75 mmol/l H3PO4 for 5 min. 
After washing three times with 75 mmol/l H3PO4 to remove any unbound [32P] ATP, 
filters were rinsed with 100% ethanol and air dried before quantification. By using a 
universal scintillation cocktail, counts were taken in a Wallac 1409 Liquid 
Scintillation Counter. The activity of protein kinase G was expressed as pmol of 32P, 
which was incorporated into the substrate (pmol/min/mg protein). 
 
 
3.2.9. Statistical analysis  
Statistical analysis was performed using GraphPad Prism 7.0 software (GraphPad 
Software, La Jolla, CA). Data are expressed as the mean ± SEM. The ordinary one-way 
ANOVA test was performed for data comparison. Differences were considered 
statistically significant at a value of p<0.05. 
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Blood glucose levels were 3.6-fold (p<0.0001), 4.6-fold (p<0.0001), and 4.7-fold 
(p<0.0001) higher in 9-, 20-, and 24-week-old db/db compared to db+/db mice, 
respectively. Stromal cell application in 20-week-old db/db mice did not affect blood 
glucose levels, nor HbA1c levels in db/db mice. Blood glucose levels were 4.5-fold 
(p<0.0001), 4.5-fold (p<0.0001), and 4.9-fold (p<0.0001) higher in 24-week-old 
WT-MSC db/db, CD362- db/db, and CD362+ db/db mice, i.e. 4 weeks post stromal 
cell injection, compared to db+/db mice, respectively (Figure 8-9A). In parallel, 
HbA1c levels were 1.7-fold (p<0.05) higher in db/db versus db+/db mice. These levels 
were not different in db/db mice receiving stromal cells, i.e. also in 24-week-old 
WT-MSC db/db, CD362- db/db, and CD362+ db/db mice, i.e. 4 weeks post stromal 
cell injection, HbA1c levels were 1.7-fold (p<0.01) higher than in db+/db mice. There 
were no differences among the different db/db groups (Figure 9B). 
 
 
Figure 8. Blood glucose progression of db+/db mice and db/db mice intravenously 
injected with/without WT-MSC, CD362-, or CD362+. Intravenous stromal cell application 
occurred in 20-week-old db/db mice, as indicated with the green arrow. All values are 
expressed as the mean ± standard deviation (SD). One-way ANOVA test, with n=9 for db+/db, 























































































4. Results  
4.1. Glucose  
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Figure 9. Impact of stromal cells on glucose and glycated hemoglobin levels in db/db 
mice 4 weeks after cell application. Bar graphs represent the mean ± SEM of A. blood 
glucose levels (mg/dl) and B. glycated hemoglobin (HbA1c) depicted as percentage in db+/db, 
db/db, and db/db mice receiving WT-MSC, CD362- or CD362+ cells. One-way ANOVA test. 
*p<0.05, **p<0.01, ***p<0.001, with n=9 for db+/db, n=6 for db/db, n=8 for WT-MSC, n=9 
for db/db CD362-, and n=9 for db/db CD362+. 
 
 
The cardiac ejection fraction (EF) is one of the key parameters to determine the global 
heart function. Within this study, no change in EF between db/db and db+/db mice 
was observed, whereas db/db CD362+ mice showed a 1.1-fold (p<0.05) lower EF than 
db+/db mice. With respect to the other treatment groups, EF was not affected in 
comparison to db/db mice (Figure 10A). In contrast to the EF, the cardiac index (CI), 
which describes the injected blood volume per minute in relation to the bodyweight 
(BW), was 1.4-fold (p<0.05) lower in db/db mice compared to db+/db mice. However, 
stromal cell application in db/db animals did not affect CI. Only CD362+-treated 
db/db mice exhibited a 1.5-fold (p<0.01) lower CI than db+/db mice (Figure 10B). 
Furthermore, the maximum LV pressure (LVPmax) did not differ between db/db and 
db+/db mice. With respect to stromal cell application, only db/db CD362+ mice 
exhibited a 1.2-fold (p<0.05) lower LVPmax compared to db+/db mice. Additionally, 
LVPmax did not differ between PBS and cell-treated db/db mice (Figure 10C). 
To further characterize the systolic function, the maximum pressure (P) rise over time 
4.2. Hemodynamic function 
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was measured (dP/dtmax). A 1.3-fold (p<0.01) decrease in db/db mice compared to 
db+/db mice was observed. This effect was abolished in db/db mice injected with 
WT-MSC cells leading to a 1.2-fold (p<0.05) higher dP/dtmax versus db/db mice. 
Furthermore, CD362- and CD362+ application led to a 1.2-fold (p<0.05) and 1.3-fold 
(p<0.001) lower dP/dtmax compared to db+/db mice, respectively (Figure 10D). 
As markers for the diastolic function, the isovolemic LV relaxation (dP/dtmin; Figure 
10E) and Tau (Figure 10F) were investigated. DP/dtmin, was 1.3-fold (p<0.05) lower 
in db/db mice compared to db+/db mice, whereas i.v. application of WT-MSC and 
CD362- increased dP/dtmin 1.3-fold (p<0.05) and 1.3-fold (p<0.05), respectively, 
versus db/db mice. In addition, dP/dtmin was 1.4-fold (p<0.01) lower in db/db CD362+ 
mice than db+/db mice (Figure 10E). With respect to the parameter Tau, db/db mice 
were characterized by a 1.2-fold (p<0.05) higher Tau compared to db+/db mice. 
Moreover, WT-MSC and db/db CD362- led to a 1.2-fold (p<0.05) and 1.1-fold 




Figure 10. Impact of stromal cells on left ventricular function in db/db mice. Bar graphs 
represent the mean ± SEM of A. Ejection fraction (EF), B. Cardiac index (CI), C. maximum 
LV pressure (LVPmax), D. maximal LVP rise rate (dP/dtmax), E. maximal LVP drop rate 
(dP/dtmin), and F. Tau in db+/db, db/db, and db/db mice receiving WT-MSC, CD362- or 
CD362+ cells. One-way ANOVA test. *p<0.05, **p<0.01, ***p<0.001, with n=9 for db+/db, 
n=6 for db/db, n=8 for WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.3.1. Left ventricular collagen I and III mRNA expression 
LV collagen 1a1 mRNA expression was 1.5-fold (p<0.05) higher in the db/db 
compared to the db+/db group, whereas only treatment with CD362- cells reduced the 
LV collagen 1a1 mRNA expression by 1.7-fold (p<0.01) versus db/db mice. LV 
collagen 1a1 was further 1.5-fold (p<0.05) lower in db/db mice CD362- compared to 
4.3. Myocardial fibrosis 
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db/db CD362+ mice (Figure 11A). In contrast to collagen 1a1, there was no 
significant difference in LV collagen 3a1 mRNA expression between db/db and 
db+/db mice. Similar to collagen 1a1, LV collagen 3a1 was 1.5-fold (p<0.05) lower in 
db/db CD362- versus db/db CD362+ mice (Figure 11B). 
 
 
Figure 11. Impact of stromal cells on left ventricular collagen I and III mRNA 
expression in db/db mice. Bar graphs represent the mean ± SEM of LV A. col1a1 and B. 
col3a1 mRNA expression in db+/db, db/db, and db/db mice receiving WT-MSC, CD362- or 
CD362+ cells. One-way ANOVA test. *p<0.05, **p<0.01, with n=9 for db+/db, n=6 for 
db/db, n=8 for WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.3.2. Left ventricular collagen I protein expression 
LV collagen I was not significantly more expressed in db/db versus db+/db mice, but 
1.3-fold (p<0.05), 1.6-fold (p<0.05), and 1.3-fold (p<0.05) higher in the LV of db/db 
WT-MSC, db/db CD362-, and CD362+ mice compared to db+/db mice, respectively 




Figure 12. Impact of stromal cells on left ventricular collagen I expression in db/db mice. 
A. Representative collagen I+ LV sections of db+/db, db/db, WT-MSC, db/db CD362-, and 
db/db CD362+ mice, at 200x magnification. B. Bar graphs represent the mean ± SEM of LV 
collagen I protein expression per heart area (HA, mm2) in db+/db, db/db, and db/db mice 
receiving WT-MSC, CD362- or CD362+ cells. One-way ANOVA test. *p<0.05, 
****p<0.0001, with n=9 for db+/db, n=6 for db/db, n=8 for WT-MSC, n=9 for db/db CD362-, 
and n=9 for db/db CD362+. 
 
 
4.3.3. Left ventricular collagen III protein expression 
Db/db mice did not establish higher LV collagen III protein levels compared to 
db+/db mice. I.v. application of stromal cells in db/db mice did not affect LV collagen 
III protein expression in db/db mice. However, in comparison to db+/db mice, 
collagen III protein expression was 1.3-fold (p<0.05) and 1.3-fold (p<0.05) lower in 
db/db WT-MSC and db/db CD362- mice, respectively (Figure 13B). 
The LV collagen I/III ratio was 1.6-fold (p<0.01) higher in db/db than in db+/db mice. 
I.v. stromal cell application did not reduce the collagen I/III ratio in db/db mice, 
leading to 1.7-fold (p<0.001), 2.0-fold (p<0.0001), and 1.5-fold (p<0.05) higher ratios 
in db/db WT-MSC, db/db CD362- and db/db CD362+ mice compared to db+/db mice, 





Figure 13. Impact of stromal cells on left ventricular collagen III expression and the 
collagen I to III ratio in db/db mice. A. Representative collagen III+ LV sections of db+/db, 
db/db, WT-MSC, db/db CD362-, and db/db CD362+ mice, at 200x magnification. B. Bar 
graphs represent the mean ± SEM of LV collagen III protein expression per heart area (HA, 
mm2) (upper panel) and of the LV collagen I / III ratio (lower panel) in db+/db, db/db, and 
db/db mice receiving WT-MSC, CD362- or CD362+ cells. One-way ANOVA test. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, with n=9 for db+/db, n=6 for db/db, n=8 for 
WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.3.4. Left ventricular alpha-smooth muscle actin mRNA expression  
LV mRNA expression of α-smooth muscle actin (α-SMA), a differentiation marker of 
myofibroblasts, was not statistically different between db/db and db+/db mice. Nor 
did i.v. stromal cell application affect the LV α-SMA mRNA in db/db mice. However, 
comparison of LV α-SMA mRNA expression in db/db CD362- versus db/db CD362+ 
mice revealed a 1.4-fold (p<0.05) lower expression in db/db CD362- compared to 




Figure 14. Impact of stromal cells on left ventricular alpha smooth muscle actin mRNA 
expression in db/db mice. Bar graphs represent the mean ± SEM of LV α-SMA mRNA 
expression in db+/db, db/db, and db/db mice receiving WT-MSC, CD362- or CD362+ cells. 
One-way ANOVA test. *p<0.05, with n=9 for db+/db, n=6 for db/db, n=8 for WT-MSC, n=9 
for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.3.5. Left ventricular alpha-smooth muscle actin protein expression  
LV α-SMA protein expression was not significantly different between the different 
experimental groups (Figure 15). 
 
Figure 15. Impact of stromal cells on left ventricular alpha smooth muscle actin 
expression in db/db mice. A. Representative α-SMA+ LV sections of db+/db, db/db, 
WT-MSC, db/db CD362-, and db/db CD362+ mice, at 200x magnification. B. Bar graphs 
represent the mean ± SEM of LV α-SMA expression per heart area (HA, mm2) in db+/db, 





























































4.3.6. Left ventricular Lox1 and Loxl2 mRNA expression 
LV Lox1 mRNA expression was 2.5-fold (p<0.01) higher in db/db than in db+/db 
mice. Stromal cell application did not lower the DM-associated induction in LV Lox1 
mRNA expression, leading to 2.2-fold (p<0.01), 2.7-fold (p<0.0001), and 2.6-fold 
(p<0.001) higher LV Lox1 mRNA expression levels in db/db WT-MSC, db/db 
CD362-, and db/db CD362+ mice versus db+/db mice, respectively (Figure 16A). LV 
Loxl2 mRNA expression was only tendentially higher in db/db mice versus db+/db 
mice, whereas WT-MSC db/db and CD362+ db/db mice displayed 1.7-fold (p<0.05) 
and 1.7-fold (p<0.05) higher LV Loxl2 mRNA expression levels compared to db+/db 
mice, respectively (Figure 16B). 
 
 
Figure 16. Impact of stromal cells on the left ventricular Lox1 and Loxl2 mRNA 
expression in db/db mice. Bar graphs represent the mean ± SEM of LV A. Lox1 and B. 
Loxl2, mRNA expression in db+/db, db/db, and db/db mice receiving WT-MSC, CD362- or 
CD362+ cells. One-way ANOVA test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, with 




4.4.1. Left ventricular presence of CD3+ cells  
CD3+ cell presence was 1.6-fold (p<0.01) higher in the LV of db/db versus db+/db 
mice. Db/db mice receiving WT-MSC, CD362-, or CD362+ cells exhibited 1.5-fold 
(p<0.05), 1.8-fold (p<0.01), and 1.7-fold (p<0.01) lower CD3+ cells in the LV, 
4.4. Inflammation 
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respectively, compared to db/db mice (Figure 17). 
 
Figure 17. Impact of stromal cells on left ventricular CD3+ cell presence in db/db mice. 
A. Representative CD3+ LV sections of db+/db, db/db, WT-MSC, db/db CD362-, and db/db 
CD362+ mice, at 200x magnification. B. Bar graphs represent the mean ± SEM of LV CD3+ 
cells present per heart area (HA, mm2) in db+/db, db/db, and db/db mice receiving WT-MSC, 
CD362- or CD362+ cells. One-way ANOVA test. *p<0.05, **p<0.01, with n=9 for db+/db, 
n=6 for db/db, n=8 for WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
4.4.2. Left ventricular presence of CD4+ cells  
The db/db group showed an up-regulated trend of CD4+ cells in the LV compared to 
the db+/db group. Furthermore, stromal cell administration did not affect the LV 
CD4+ cell presence in db/db mice (Figure 18). 
 
Figure 18. Impact of stromal cells on left ventricular CD4 cell presence in db/db mice. A. 
Representative CD4+ LV sections of db+/db, db/db, WT-MSCs, db/db CD362-, and db/db 
CD362+ mice, at 200x magnification. B. Bar graphs represent the mean ± SEM of LV CD4+ 
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cells present per heart area (HA, mm2) in db+/db, db/db, and db/db mice receiving WT-MSC, 
CD362- or CD362+ cells. One-way ANOVA test, with n=9 for db+/db, n=6 for db/db, n=8 for 
WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
4.4.3. Left ventricular presence of CD8a+ cells  
Db/db mice exhibited 1.4-fold (p<0.01) higher presence of CD8a+ cells in the LV 
compared to db+/db mice. Stromal cell application did not affect the presence of 
CD8a+ cells in the LV of db/db mice (Figure 19). 
 
 
Figure 19. Impact of stromal cells on left ventricular CD8a cell presence in db/db mice. 
A. Representative CD8a+ LV sections of db+/db, db/db, WT-MSC, db/db CD362-, and db/db 
CD362+ mice, at 200x magnification. B. Bar graphs represent the mean ± SEM of LV CD8a+ 
cells present per heart area (HA, mm2) in db+/db, db/db, and db/db mice receiving WT-MSC, 
CD362- or CD362+ cells. One-way ANOVA test. **p<0.01, with n=9 for db+/db, n=6 for 
db/db, n=8 for WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.4.4. Left ventricular presence of CD68+ cells  
The presence of CD68+ cells was tendentially increased in the LV of db/db versus 
db+/db mice. I.v. application of WT-MSC, CD362- or CD362+ cells in db/db mice 
reduced the LV presence of CD68+ cells by 1.6-fold (p<0.05), 1.8-fold (p<0.01), and 




Figure 20. Impact of stromal cells on left ventricular CD68 cell presence in db/db mice. 
A. Representative CD68+ LV sections of db+/db, db/db, WT-MSC, db/db CD362-, and db/db 
CD362+ mice, at 200x magnification. B. Bar graphs represent the mean ± SEM of LV CD68+ 
cells present per heart area (HA, mm2) in db+/db, db/db, and db/db mice receiving WT-MSC, 
CD362- or CD362+ cells. One-way ANOVA test. *p<0.05, **p<0.01, with n=9 for db+/db, 
n=6 for db/db, n=8 for WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.4.5. Left ventricular cytokines mRNA expression  
LV TNF-α mRNA expression was not increased in db/db mice versus db+/db mice. 
I.v. application of WT-MSC and CD362- in db/db mice resulted in 1.6-fold (p<0.05) 
and 1.5-fold (p<0.05) lower LV TNF-α mRNA expression levels compared to db+/db 
mice, but these levels were not significantly different from db/db mice. In addition, 
LV TNF-α mRNA expression in db/db CD362+ mice was not different from that in 
db/db mice (Figure 21A). LV TGF-β mRNA expression was tendentially higher in 
db/db versus db+/db mice. Stromal cell treatment did not affect LV TGF-ß mRNA in 
db/db mice, whereas i.v. injection of WT-MSC in db/db mice induced the LV TGF-ß 
mRNA by 1.3-fold (p<0.05) compared to db+/db mice. The TGF-ß mRNA expression 
levels in the LV of db/db WT-MSC mice were also 1.3-fold (p<0.05) higher than in 
db/db CD362- mice (Figure 21B). Also with respect to LV IL-10 mRNA expression, 




Figure 21. Impact of stromal cells on the left ventricular cytokine mRNA expression in 
db/db mice. Bar graphs represent the mean ± SEM of LV A. TNF-α, B. TGF-ß, and C. IL-10 
mRNA expression in db+/db, db/db, and db/db mice receiving WT-MSC, CD362- or CD362+ 
cells. One-way ANOVA test. *p<0.05, with n=9 for db+/db, n=6 for db/db, n=8 for WT-MSC, 
n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
 
4.4.6. Left ventricular mRNA expression of components of the Nlrp3 
inflammasome 
Db/db mice exhibited 2.7-fold (p<0.01) higher LV Nlrp3 mRNA expression levels 
compared to db+/db mice. Both the injection of WT-MSC and of CD362- cells 
reduced LV Nlrp3 expression by 2.3-fold (p<0.05) and 2.4-fold (p<0.01), respectively. 
The 1.9-fold decrease in LV Nlrp3 expression in db/db CD362+ versus db/db mice did 
not reach statistical significance (p=0.089) (Figure 22A). In parallel to the LV Nlrp3 
mRNA expression, LV ASC mRNA expression was 1.7-fold (p<0.01) higher in db/db 
mice compared to db+/db mice. This effect was abrogated in db/db mice injected with 
WT-MSC or CD362- cells, leading to a 1.4-fold (p<0.05) and 1.5-fold (p<0.05) lower 
ASC mRNA expression levels compared to db/db mice, respectively, and levels not 
different from db+/db controls (Figure 22B). Concomitant with the LV expression 
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levels of the Nlrp3 inflammasome components Nlrp3 and ASC, LV caspase 1 mRNA 
expression was 1.7-fold (p<0.01) higher in db/db compared to db+/db mice, whereas 
its expression was 1.6-fold (p<0.05) lower in db/db CD362- compared to db/db mice. 
There was no significant difference in the LV caspase 1 mRNA expression of 
WT-MSC db/db and CD362+ db/db mice compared to db/db mice (Figure 22C). 
Interestingly, LV IL-1β mRNA expression was 1.9-fold (p<0.05) lower in db/db 
versus db+/db mice and 1.7-fold (p<0.05) lower in db/db WT-MSC compared to 
db+/db mice (Figure 22D).  
 
 
Figure 22. Impact of stromal cells on the left ventricular mRNA expression of 
components of the Nlrp3 inflammasome in db/db mice. Bar graphs represent the mean ± 
SEM of LV A. Nlrp3, B. ASC, C. caspase-1, and D. IL-1β mRNA expression in db+/db, 
db/db, and db/db mice receiving WT-MSC, CD362- or CD362+ cells. One-way ANOVA test. 
*p<0.05, **p<0.01, with n=9 for db+/db, n=6 for db/db, n=8 for WT-MSC, n=9 for db/db 
CD362-, and n=9 for db/db CD362+. 
 
 
To assess the impact of the different stromal cells on the systemic immune status in 
db/db mice, flow cytometry on splenocytes isolated from the different experimental 
4.5. Immune regulation in splenocytes 
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groups was determined. The percentage of CD68+TGF-β+ cells was not significantly 
different in the splenocytes of db/db mice versus db+/db mice. Interestingly, the 
percentage of TGF-ß expressing CD68 cells was 2.1-fold (p<0.0001) lower and 
2.0-fold (p<0.0001) higher in db/db CD362- and db/db CD362+ compared to db+/db 
mice, respectively (Figure 23A). With respect to MNCs activation, db/db mice 
displayed a 1.2-fold (p<0.01) higher MNCs activation/proliferation compared to 
db+/db mice. WT-MSC db/db mice exhibited a 1.1-fold (p<0.05) lower splenic 
MNCs activation than db/db mice, whereas the MNCs activity in db/db CD362- and 
db/db CD362+ was not significantly different from db/db mice (Figure 23B). The 
percentage of Tregs in the spleen was not significantly different between db/db and 
db+/db mice. I.v. application of CD362+ cells raised the percentage of Tregs leading 
to 1.3-fold (p<0.0001), 1.3-fold (p<0.001), 1.3-fold (p<0.001) 1.4-fold (p<0.0001) 
higher percentage of Tregs compared to db+/db, db/db, WT-MSC db/db, and CD362- 
db/db mice, respectively (Figure 23C). In contrast to the unchanged percentage in 
Tregs between db/db and db+/db mice, the percentage of apoptotic Tregs was 1.6-fold 
(p<0.0001) higher in db/db compared to db+/db mice. Stromal cell application in 
db/db mice decreased the percentage of apoptotic Tregs versus db/db mice resulting 
in a 1.7-fold (p<0.0001), 1.8-fold (p<0.0001), and 1.4-fold (p<0.0001) lower 
percentage of apoptotic Tregs in db/db WT-MSC, db/db CD362-, and db/db CD362+ 




Figure 23. Impact of stromal cells on the immune status of splenocytes isolated from 
db/db mice. Bar graphs represent the mean ± SEM of A. TGF-ß-expressing CD68 cells, B. 
the division index of total MNCs, C. Tregs represented as CD4CD25FoxP3+ cells depicted as 
the percentage of CD4 cells, and D. apoptotic Tregs represented as Annexin V+ 
CD4CD25FoxP3+ cells depicted as the percentage of CD4CD25FoxP3+ cells from db+/db, 
db/db, and db/db mice receiving WT-MSC, CD362-, or CD362+ cells. One-way ANOVA test. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, with n=9 for db+/db, n=6 for db/db, n=8 for 
WT-MSC, n=9 for db/db CD362-, and n=9 for db/db CD362+. 
 
To assess the impact of i.v. stromal cell application on the pro-fibrotic potential of 
splenocytes in db/db mice, splenocytes of the different experimental groups were 
co-cultured on fibroblasts and their impact on collagen deposition of fibroblasts was 
determined. Collagen deposition was 1.2-fold (p<0.05) higher upon co-culture of 
fibroblasts with splenocytes derived from db/db mice compared to splenocytes from 
db+/db mice, indicating a higher pro-fibrotic potential of db/db splenocytes versus 
db+/db splenocytes. Only splenocytes isolated from db/db mice injected with CD362+ 
cells induced a 1.3-fold (p<0.01) lower collagen deposition in fibroblasts compared to 
db/db splenocytes. Splenocytes from db/db WT-MSC and db/db CD362- did not lead 
4.6. Assessment of the pro-fibrotic potential of splenocytes 
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to a lower collagen production in fibroblasts upon co-culture compared to splenocytes 
from db/db mice (Figure 24B). 
 
 
Figure 24. Impact of stromal cells on the pro-fibrotic capacity of splenocytes isolated 
from db/db mice. A. Experimental design illustrating that splenocytes isolated from the 
different experimental groups were co-cultured on murine fibroblasts for 1 day. Next, 
splenocytes were removed and collagen deposition of murine fibroblasts was determined via 
Sirius Red staining. B. Bar graphs represent the mean ± SEM of the absorbance at 540 nm, 
depicting the collagen deposition of monocultured murine fibroblasts or fibroblasts 
co-cultured with splenocytes isolated from db+/db, db/db, and db/db mice receiving 
WT-MSC, CD362-, or CD362+ cells. One-way ANOVA test. *p<0.05, **p<0.01, with n=9 




To further understand our findings, a hypothesis-free proteome analysis was 
performed via imaging mass spectrometry (Figure 25). Principal component analysis 
of LVs from db+/db, db/db, and db/db mice i.v. injected with WT-MSC, CD362+, or 
CD362- cells clearly distinguished different protein patterns between the groups. 




Figure 25. Cluster analysis of principal component analysis of left ventricles from 
db+/db (control), db/db, and db/db mice i.v. injected with WT-MSC, CD362+, or CD362- 
cells. 
 
Further analysis indicated a lower expression of the sarcomere protein titin N2B 
isoform in db/db versus db+/db mice, which could be overcome by i.v. application of 
all investigated stromal cells (Figure 26). 
 
Figure 26. Imaging mass spectrometry analysis. Spatial distribution of characteristic m/z 
values of Titin N2B in left ventricles of db+/db, db/db, and db/db mice i.v. injected with 
WT-MSC, CD362- and CD362+ cells. Average peak intensity and distribution of 2092.5 Da 
in left ventricles from db+/db (control), db/db, and db/db mice i.v. injected with WT-MSC, 
CD362+ and CD362- cells. The m/z-values 2095.5 Da show a significantly higher intensity 
(AUC>0.75 p<0.01) in db+/db (control) compared to db/db, and db/db mice i.v. injected with 
WT-MSC, CD362+, or CD362- cells. Still, the m/z-values 2095.5 Da show significantly lower 
intensity in db/db in comparison to db/db mice i.v. injected with WT-MSC, CD362+ and 
CD362- cells (AUC< 0.25 p<0.01). 
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In addition, the phosphorylation state of N2B titin was 1.8-fold (p<0.01) lower in 
db/db versus db+/db mice. Interestingly, the decreased phosphorylation state of N2B 
was 1.6-fold (p<0.05) and 1.5-fold (p<0.05) upregulated in the db/db mice receiving 
WT-MSC and CD362- cells, respectively, whereas i.v. application of CD362+ cells 
had no effect on the phosphorylation of titin N2B compared to the db/db mice 
(Figure 27A). In agreement with the phosphorylation of N2B, protein kinase G 
activity was 1.5-fold (p<0.05) lower in db/db versus db+/db mice and was 1.5-fold 
(p<0.05) and 1.5-fold (p<0.05) higher in db/db WT-MSC and db/db CD362- mice, 
respectively. Also here, there was no significant difference in the protein kinase G 
activity between the db/db and the db/db CD362+ group (Figure 27B). 
 
 
Figure 27. Impact of stromal cells on the titin 2B phosphorylation state and on the 
protein kinase G activity in the left ventricle of db/db mice. Bar graphs represent the mean 
± SEM of the LV A. Titin N2B ser/Thr phosphorylation state depicted as the percentage of 
phosphorylation towards total protein and B. protein kinase G activity in db/db mice. 




The present study was focused on evaluating the impact of i.v. applied WT-MSC, 
CD362+ and CD362--selected MSCs in diabetic db/db mice. In brief, only application 
of WT-MSC and CD362- cells improved LV function, as indicated by increased 
contractility and reduced cardiac stiffness compared to db/db mice (Figure 10). 
Further investigations showed that only WT-MSC and CD362- cells reduced the LV 
expression of the components of the Nlrp3 inflammasome (Figure 22). Additionally, 
a decreased number of splenic apoptotic Tregs was observed among all cell-treated 
db/db groups compared to db/db mice (Figure 23), whereas a reduction in the 
pro-fibrotic capacity of splenocytes could only be found in the splenocytes of db/db 
CD362+ mice (Figure 24). Proteome analysis via imaging mass spectrometry showed 
that the sarcomere protein titin was downregulated in db/db mice, which could be 
overcome after stromal cell application in db/db mice (Figure 26). In agreement with 
cardiac function, subsequent analysis of all titin phosphorylation showed a drop 
within the db/db group, which could only be restored by application of WT-MSC and 
CD362- cells (Figure 27). 
 
Elevated blood glucose levels are one of the main characteristics of DM. Previous 
studies in humans [98][99][100] and mice [65][66][101] have shown a therapeutic 
effect in glycemic control after MSCs treatment. This phenomenon was explained by 
the regenerative properties of MSCs, including their capacity to differentiate into 
insulin-producing cells [65], and their ability to repair pancreatic ß cells in a paracrine 
manner, including an increase in islet capillary density and reduction in ß-cell 
apoptosis [67][102]. In contrast to the abovementioned findings, we (and other 
partners of the REDDSTAR consortium) could not observe changes after cell 
application neither in blood glucose levels nor in the HbA1C value compared to db/db 
mice (Figure 8 and 9). This discrepancy can be explained by the fact that we used an 
5. Discussion 
5.1. WT-MSC, CD362+, and CD362- cells did not improve blood glucose levels 
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allogeneic MSCs approach i.e. human WT-MSC and CD362- and CD362+ cells were 
injected in immunocompetent mice. However, Lee et al. [65] used human MSCs, but 
in severe combined immunodeficient (SCID) mice, whereas Ezquer et al. [66] used 
murine MSCs injected in diabetic mice. Finally, Hao et al. [101] observed a decrease 
in blood glucose levels following human MSCs application in experimental type 2 
diabetes rats, but here MSCs were administrated at different timepoints. 
 
 
Numerous in vivo studies have shown that MSCs application improves cardiac 
function [103][104][105], involving their ability to migrate towards the injured region 
[106] following i.v. injection [60]. In the present study, we investigated the heart 
function via conductance catheter. In line with the cardioprotective properties of 
MSCs, WT-MSC and CD362- cells improved LV function, as shown by the increase 
in dP/dtmax, and reduction of dP/dtmin and Tau (Figure 10). 
Impaired cardiac contractility is commonly associated with excessive cardiac fibrosis 
[107]. In our study, there was no induction of cardiac fibrosis in the db/db versus 
db+/db mice as indicated by no increased LV collagen I (Figure 12) and collagen III 
(Figure 13) protein expression in db/db mice versus db+/db mice. Activated 
fibroblasts, also called myofibroblasts, are the main producers of collagen during 
heart failure [108]. LV α-SMA protein expression, the marker of myofibroblasts, was 
not elevated in any experimental diabetic group. However, the ratio of collagen I (stiff 
form) towards collagen III (compliant form) [109] was increased in db/db versus 
non-diabetic mice. This change in collagen ratio might be connected to the reduced 
LV function of db/db versus db+/db mice. However, in contrast to cardiac function, 
none of the different stromal cells reduced the collagen I / III ratio, indicating that this 
altered ratio is probably not the major cause underlying cardiac dysfunction in these 
db/db mice. In fact, it has recently been demonstrated that dysregulation of the 
sarcomere protein titin alone (paragraph 5.5.), in the absence of cardiac fibrosis, may 
influence cardiac function in a rat model of the metabolic syndrome [110]. 
5.2. WT-MSC and CD362- cells ameliorate left ventricular function 
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Furthermore, impaired endothelial function [111] and vascular rarefaction [112] may 
underlie impaired diastolic relaxation. Numerous studies have demonstrated 
MSC-mediated cardiac repair via promoting angiogenesis followed by an ameliorated 
cardiac function [113][114], whereas the impact of MSCs on titin regulation has not 
been demonstrated so far. In this study, we explored the impact of stromal cell 
application on titin regulation in db/db mice (paragraph 5.5.), but the evaluation of 
the impact of stromal cell application on cardiac capillary density and arteriole 
density requires still further investigation. It is interesting to note that De Rossi et al. 
[115] demonstrated that released syndecan 2 (CD362) has anti-angiogenic effects in a 
xenograft tumor model. The authors detected a reduced endothelial cell migration 
based on CD148 interaction, paralleled by inactivation of β1 integrin and finally 
decreased tumor size. Additionally, induced apoptosis was observed in osteosarcoma 
cells overexpressing CD362 [116]. Both findings could be helpful to understand the 
poor cardiac function after application of CD362+ cells. 
 
 
After investigating cardiac function and fibrosis, we next analyzed myocardial 
inflammation and immune cell presence as well as splenic immune cell modulation. 
Inflammatory mediators – among others TNF-α [117], TGF-β [118], and IL-1β [119] 
can induce heart failure through several mechanisms, including promotion of cardiac 
fibrosis [117][120][119], cardiac monocyte infiltration [121], and/or the ability to 
exert a direct negative inotrope effect. In our study, no relevant changes of cardiac 
TNF-α, TGF-β, and IL-10 mRNA expression were observed between diabetic db/db 
and db+/db control mice (Figure 21), whereas LV IL-1ß mRNA was reduced in 
db/db versus db+/db mice (see paragraph 5.4, Figure 22). Nevertheless, we detected 
enhanced cardiac presence of CD3+ (Figure 17) and of CD8a+ cells (Figure 19) in 
db/db mice compared to controls, whereas stromal cell application decreased cardiac 
CD3+ cells in db/db mice. However, no significant differences in cardiac CD8a+ cells 
5.3. WT-MSC, CD362+, and CD362- cells influence cardiac immune cell 
presence and modulate splenic immune cell activation 
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were found after stromal cell application in db/db mice versus PBS-treated db/db 
mice. I.v. application of WT-MSC, CD362-, and CD362+ cells in db/db mice 
decreased the cardiac presence of CD68+ cells in db/db mice (Figure 20). These 
findings are in line with the well-established immunomodulatory properties of MSCs. 
MSCs have been shown to inhibit T cell proliferation [122][123] and to reduce cardiac 
MNCs activation [124] and cardiac pro-inflammatory Ly6Chigh and Ly6Cmiddle 
monocytes presence [125]. 
Besides the heart, we evaluated the impact of i.v. application of WT-MSC, CD362- and 
CD362+ cells on systemic immunomodulation. For this purpose, we examined the 
influence of stromal cell application on the percentage of TGF-ß-expressing CD68+ 
cells, Tregs, apoptotic Tregs, and MNCs activation in the spleen, as well as the 
pro-fibrotic potential of splenocytes in db/db mice. The spleen was chosen, given the 
relevance of the cardiosplenic axis, i.e. the homing of immune cells from the spleen 
towards the heart and their subsequent involvement in cardiac remodeling in heart 
failure [126]. In accordance with observations in ob/ob mice [127], splenic MNCs 
activity was induced in diabetic db/db versus db+/db mice (Figure 23). This activity 
was lower in db/db mice, which received WT-MSC, but not in db/db mice injected with 
CD362- nor CD362+ cells. The quantity of Tregs, known for their anti-fibrotic and 
anti-inflammatory properties [128][129][130], was not lower in db/db versus control 
mice, whereas their quality was impaired in the diabetic db/db compared to control 
mice as indicated by an induction in apoptotic Tregs. The percentage of apoptotic Tregs 
in db/db mice could be decreased by all stromal cells, whereas only CD362+ cells raised 
the percentage of Tregs in db/db mice. These findings are supported by the ability of 
MSCs to increase Tregs [56]. Interestingly, only i.v. injection of CD362+ cells reduced 
the pro-fibrotic potential of splenocytes in db/db mice (Figure 24). This can partly be 
explained by the observation that only CD362+ cells induced the percentage of splenic 
Tregs, known for their anti-fibrotic properties [129] in db/db mice. On the other hand, 
also only CD362+ db/db mice displayed an increase in splenic CD68 cells expressing 
the pro-fibrotic factor TGF-ß, indicating that the final lower pro-fibrotic potential of 
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splenocytes from CD362+ db/db mice is due to a delicate change in pro- versus 
anti-fibrotic mediators. 
 
The innate immune system recognizes danger-associated molecular patterns (DAMP) 
via pattern recognition receptors resulting, among others, in the activation of the 
inflammasome-3 [131][132]. The Nlrp3 inflammasome has effects in 
auto-inflammatory diseases and is associated with metabolic dysfunction [133]. It 
promotes obesity-induced autoinflammation and insulin resistance [134]. Danger 
signals induced by DM such as fatty acids [135], uric acid [136], endoplasmic 
reticulum stress [137], and reactive oxygen species [138] activate the Nlrp3 
inflammasome. Subsequently, pro-inflammatory cytokines, which are 
inflammasome-dependent, induce insulin resistance and cause death of β-cells in the 
pancreas [139]. In the heart, the number of inflammasomes per field is higher in 
patients presenting with severe heart failure (NYHA III–IV) versus those with mild or 
no heart failure [140], indicating the relevance of the Nlrp3 inflammasome in heart 
failure. 
With respect to our findings, LV Nlrp3, ASC, and caspase-1 mRNA expression was 
significantly induced in db/db mice compared to the control group. I.v. application of 
WT-MSC and CD362- cells decreased LV Nlrp3, and ASC gene expression, while 
CD362+ cells had no effect. Moreover, only CD362- cells were able to reduce LV 
caspase-1 mRNA expression in db/db mice. Our findings with WT-MSC are 
supported by previous studies demonstrating that the anti-inflammatory effects of 
MSCs include the downregulation of the inflammasome [141][142]. However, the 
present study is the first to demonstrate the impact of MSCs on the Nlrp3 
inflammasome under diabetic conditions. Interestingly, our findings show lower LV 
IL-1ß mRNA expression in db/db versus control db+/db mice, which might be the 
result of a negative feedback mechanism in the presence of higher LV IL-1ß protein 
levels (Figure 22). Further studies are necessary to investigate whether WT-MSC and 
5.4. WT-MSC and CD362- cells reduce the expression of components of the 
Nlrp3 inflammasome 
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CD362- cells reduce the NF-κB-dependent expression of Nlrp3, downstream the 
pattern recognition receptors NOD2 and TLR, which are also induced under DM [127] 
[143], and/or whether they also reduce the activity of the Nlrp3 inflammasome via the 
anti-oxidative properties of MSCs as shown by Oh et al. [144]. In this context, it will 
be necessary to evaluate caspase 1 activity and IL-1ß protein expression as endpoint 
of inflammasome activity following cleavage of pro-IL-1ß via caspase 1 [144].  
 
 
Imaging mass spectrometry is a novel technique to determine region-dependent 
protein expression levels on tissue sections [97]. In the present study, imaging mass 
spectrometry revealed a significantly lower N2B isoform expression in db/db mice 
compared to db+/db mice (Figure 26), an effect which could be overcome by the 
application of WT-MSC, CD362- and CD362+ cells. Titin is the largest sarcomere 
protein and exists in two isoforms: N2B and N2BA. Besides collagen, also titin 
influences cardiac function. A shift in isoform expression or titin 
hypophosphorylation results in the development of cardiac dysfunction 
[110][145][146]. Therefore, our imaging mass spectrometry findings are not 
conclusive and further evaluation on protein level is required to confirm the changes 
in N2B expression in relation to the N2BA isoform to show a possible relation to the 
observed cardiac dysfunction. However, we could demonstrate that the 
phosphorylation of the N2B isoform was downregulated in db/db mice and 
interestingly, that in line with cardiac function it could only be restored in db/db mice, 
which received WT-MSC or CD362- cells (Figure 27). DM is associated with 
oxidative stress and with particular changes in guanylyl cyclase intracellular pathways 
leading to a reduction in cyclic guanosine monophosphate (cGMP) levels [147] and 
subsequent low protein kinase G activity, leading to titin hypophosphorylation, which 
is associated with cardiomyocyte stiffness [20] [148]. Activation of protein kinase G 
via cGMP signaling can lower diastolic tone and increase LV extensibility [149] 
[150]. As shown in Figure 27, protein kinase G activity was downregulated in db/db 
5.5. WT-MSC and CD362- cells increase cardiac titin phosphorylation 
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mice. Concomitant with the titin phosphorylation state, only the application of 
WT-MSC and CD362- cells normalized protein kinase G activity to control levels. In 
summary, the data indicate that the normalized titin phosphorylation and protein 
kinase G activity in db/db mice which received WT-MSC or CD362- cells underlie, 
be it in part, the improved cardiac function in those mice compared to untreated db/db 
mice and db/db mice which received CD362+ cells. 
 
This is the first study evaluating the impact of CD362+-selected MSCs on cardiac 
function in mice. Consequently, there are no other studies available to reflect and 
understand the effect of CD362+ cells in the db/db setting. At the present stage, this 
study is only descriptive and does not give any possible in-depth mechanism 
explaining the negative outcome of the CD362+ cells following i.v. application in 
db/db mice. In order to gain a better understanding of the CD362+ cells and their 
working mechanism, further knowledge of syndecans and particularly CD362 is 
required. Syndecans are single transmembrane domain proteins. These core proteins 
carry three to five heparan sulfate and chondroitin sulfate chains, and one of their 
main functions is the interaction with, and modulation of, a large variety of ligands 
[151]: they can carry and interact with fibroblast growth factors, vascular endothelial 
growth factor and also with TGF-β and TNF-α. These pleiotropic cytokines can lead 
to a disturbance of systolic and diastolic function by several mechanisms. In our 
experiment, only WT-MSC and CD362- db/db mice exhibited lower LV TNF-α 
mRNA expression versus db/db mice, whereas CD362+ db/db mice did not (Figure 
21A). In addition, the percentage of splenic CD68 cells expressing TGF-ß was higher 
in CD362+ db/db mice versus db/db, WT-MSC db/db and CD362- db/db mice (Figure 
23A). This suggests that interactions of CD362+ with TGF-ß and TNF-α [151] may 
contribute to these observations. In vitro studies with CD362+ cells co-cultured with 
immune cells, cardiac fibroblasts and cardiomyocytes are required to understand the 
impact of CD362+ cells on cytokine expression, immune cell modulation, collagen 
production in cardiac fibroblasts, and titin regulation in cardiomyocytes, respectively. 
5.6. Perspectives 
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Furthermore, the engraftment of WT-MSC, CD362-, and CD362+ cells in the heart, 
lung, spleen, liver, pancreas, and kidney following i.v. application in db/db mice 
should still be evaluated to verify that differences in their impact on cardiac function 
might be due to differences in engraftment. Last but not least, the impact of the 
different stromal cells on cardiac capillary and arteriole density in db/db mice should 
still be determined, given the relevance of an impaired angiogenesis and vascular 
rarefaction on diastolic dysfunction.  
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